- ►endojournals.org A Mari, WM Sallas, YL He, C Watson, M … - Journal of Clinical …, 2005 - Endocrine Soc Results: Vildagliptin significantly increased the insulin secretory rate at 7 mmol/liter glucose
(secretory tone), calculated from the dose response; the difference in least squares mean (
LSM) was 101 ± 51 pmol·min –1 ·m –2 (P = 0.002). The slope of the ß-cell dose response, ... Cited by 198 - Related articles - BL Direct - All 8 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ... Cited by 179 - Related articles - All 25 versions
- ►endojournals.org JM Egan, AR Clocquet, D Elahi - Journal of Clinical Endocrinology & …, 2002 - Endocrine Soc Exendin-4 is a potent and long-acting agonist of the glucagon-like peptide-1 (GLP-1)
receptor. GLP-1 is an insulinotropic gut peptide and is being evaluated for the regulation of plasma
glucose in type 2 diabetes. The purpose of the present study was to ascertain whether ... Cited by 161 - Related articles - BL Direct - All 4 versions
- ►endojournals.org JJ Meier, B Gallwitz, S Salmen, O Goetze, JJ … - Journal of Clinical …, 2003 - Endocrine Soc The effects of different iv doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and
gastric emptying were compared in patients with type 2 diabetes. Twelve patients with type 2
diabetes received three different infusion rates of GLP-1 (0.4, 0.8, and 1.2 pmol/kg·min) or ... Cited by 122 - Related articles - BL Direct - All 5 versions
- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ... Cited by 119 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org LA Nikolaidis, D Elahi, T Hentosz, A Doverspike, R … - Circulation, 2004 - Am Heart Assoc Background— The failing heart demonstrates a preference for glucose as its metabolic
substrate. Whether enhancing myocardial glucose uptake favorably influences left ventricular
(LV) contractile performance in heart failure remains uncertain. Glucagon-like peptide-1 ( ... Cited by 104 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org JA Pospisilik, SG Stafford, HU Demuth, CHS McIntosh, … - Diabetes, 2002 - Am Diabetes Assoc Upon release into circulation, the potent insulin secretagogues glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are rapidly cleaved and inactivated by
the enzyme dipeptidyl peptidase IV (DP IV). Long-term administration of specific DP IV ... Cited by 99 - Related articles - BL Direct - All 6 versions
JJ Meier, MA Nauck - Diabetes/Metabolism Reviews - interscience.wiley.com Post-translational proteolytic processing of the preproglucagon gene in the gut results in the
formation of glucagon-like peptide 1 (GLP-1). Owing to its glucose-dependent insulinotropic
effect, this hormone was postulated to primarily act as an incretin, ie to augment insulin ... Cited by 73 - Related articles - All 3 versions
- ►endojournals.org JM Egan, GS Meneilly, JF Habener, D Elahi - Journal of Clinical …, 2002 - Endocrine Soc The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is being examined as a potential
new agent for treatment in type 2 diabetic patients. Whereas the insulinotropic properties of this
peptide are well established, another property of the hormone, an insulinomimetic effect ... Cited by 60 - Related articles - BL Direct - All 8 versions
